NCT01948921View on ClinicalTrials.gov

Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Patients Undergoing Diagnostic EGD
Interventions
DRUG

placebo

DRUG

Meperidine

Trial Locations (1)

622

Buddhist Dalin Tzu Chi General Hospital, Chiayi City

All Listed Sponsors
lead

Dalin Tzu Chi General Hospital

OTHER

NCT01948921 - Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy. | Biotech Hunter | Biotech Hunter